Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829639 | 0.85 | RAD52 (0.47) | SLC6A4POLBRAD52ALDH1A1MAPK1 | |
| SCHEMBL17829792 | 0.80 | POLB (0.44) | POLBRAD52ALDH1A1MAPK1KMT2A | |
| SCHEMBL17829798 | 0.78 | POLB (0.53) | POLBRAD52ALDH1A1MAPK1KMT2A | |
| SCHEMBL17829651 | 0.78 | CCR4 (0.39) | SLC6A4ARFLT3 | |
| SCHEMBL17829853 | 0.78 | RAD52 (0.53) | POLBRAD52ALDH1A1MAPK1KMT2A | |
| SCHEMBL17829886 | 0.78 | POLB (0.55) | POLBRAD52ALDH1A1MAPK1KMT2A | |
| SCHEMBL17833017 | 0.77 | CCR4 (0.47) | FLT3 | |
| SCHEMBL17829569 | 0.77 | POLB (0.45) | POLBRAD52ALDH1A1MAPK1KMT2A | |
| SCHEMBL17829817 | 0.76 | RAD52 (0.55) | POLBRAD52ALDH1A1MAPK1KMT2A | |
| SCHEMBL17830139 | 0.75 | RAD52 (0.57) | POLBRAD52ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | SLC6A4 3100/4885POLB 1188/4885RAD52 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.